Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Kringle Pharma, Inc.. A complete text table follows the diagram.
Limited reported sales are outweighed by research and administrative spending.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research and development | 1 | 376M | 68.0% of reported total |
| Other SG&A | 1 | 176M | 32.0% of reported total |
| Biotech operating expense base | 2 | 552M | Reported six-month total · ¥552M |
| Operating loss | 2 | 515M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 1.1B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research and development | Biotech operating expense base | 376M |
| Other SG&A | Biotech operating expense base | 176M |
| Biotech operating expense base | Operating costs & expenses | 552M |
| Operating loss | Operating costs & expenses | 515M |